Showing results (1041-1050 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 9, 2019
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesotheliomaEmilie M J van Brummelen, Evgeny Levchenko, Manuel Dómine, et al.
Investigational New Drugs|January 1, 1986
A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanomaF L Meyskens, E M Kingsley, T Glattke, et al.
Investigational New Drugs|April 18, 2019
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κBSuat Erdogan, Kader Turkekul, Ilker Dibirdik, et al.
Investigational New Drugs|April 18, 2019
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinomaYen-Bin Hsu, Ming-Chin Lan, Yu-Lun Kuo, et al.
Investigational New Drugs|March 12, 2022
An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancerTakuro Mizukami, Keiko Minashi, Hiroki Hara, et al.
Investigational New Drugs|June 9, 1999
Cryptophycin 1 cellular levels and effects in vitro using L1210 cellsB J Foster, M Fortuna, J Media, et al.
Investigational New Drugs|June 9, 1999
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687)H Hochster, R Oratz, D S Ettinger, et al.
Investigational New Drugs|June 9, 1999
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancerS Mani, J W Kugler, J A Knost, et al.
Investigational New Drugs|November 11, 1999
Current status of pyrazoloacridine as an anticancer agentA A Adjei
Investigational New Drugs|November 11, 1999
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancerD Rischin, L K Webster, M J Millward, et al.
Pageof 372